Startpage

Isofol’s Board of Directors decides to initiate the planning of clinical studies and will announce a strategic development plan on March 19

GOTHENBURG, Sweden, February 14, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), has been engaged in intensive strategy work since the new Board of Directors and management took office in January. The Board of Directors has decided today to prepare a new development program for arfolitixorin, with the goal of initiating new clinical studies as soon as possible. The company intends to present details of the strategic direction on March 19, along with holding an investor meeting.

Isofol’s Board of Directors decides to initiate the planning of clinical studies and will announce a strategic development plan on March 19 Read More »

Isofol appoints Petter Segelman Lindqvist as new CEO

GOTHENBURG, Sweden, January 9, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company’s Board of Directors has appointed Petter Segelman Lindqvist as new Chief Executive Officer. He has extensive experience from leading roles in several international pharmaceutical companies and takes up the position with immediate effect.

Isofol appoints Petter Segelman Lindqvist as new CEO Read More »

Isofol presents additional results from laboratory tests with arfolitixorin showing supplementary effects

GOTHENBURG, Sweden, December 28, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company has received additional results from the laboratory tests conducted with arfolitixorin ahead of a potential decision on the drug candidate’s continued clinical development. The results show interesting supplementary effects of arfolitixorin in two of a total of five evaluated organoids from colorectal cancer tumors. These findings are positive for Isofol and the company will implement additional bioinformatic analysis to identify potential patterns.

Isofol presents additional results from laboratory tests with arfolitixorin showing supplementary effects Read More »

Isofol’s board of directors announces its position on minority shareholder’s proposal ahead of extraordinary general meeting

GOTHENBURG, Sweden, December 13, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that all of the company’s board members will leave their respective positions if Jan-Eric Österlund is elected as a new member of the board at the extraordinary general meeting that has been convened on a request from a group of minority shareholders.

Isofol’s board of directors announces its position on minority shareholder’s proposal ahead of extraordinary general meeting Read More »

Isofol has received the first results from laboratory tests of arfolitixorin

GOTHENBURG, Sweden, December 7, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company has received the first results from the laboratory tests of arfolitixorin which are performed ahead of a potential decision to continue the clinical development of the drug candidate. Data generated so far from the first experiments show no difference in additional effect of arfolitixorin compared to leucovorin. Higher doses of arfolitixorin than was used in the AGENT study have been tested, but with no better effect. Further laboratory tests are ongoing and full results from the preclinical evaluation are expected to be delivered in early 2024.

Isofol has received the first results from laboratory tests of arfolitixorin Read More »

Notice convening the Extraordinary General Meeting in Isofol Medical AB (publ) 4 January 2024

GOTHENBURG, Sweden, November 21, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical AB (publ), Reg. No. 556759-8064 based in Gothenburg, to the Extraordinary General Meeting on Thursday, January 4, 2024.

Notice convening the Extraordinary General Meeting in Isofol Medical AB (publ) 4 January 2024 Read More »

Scroll to Top